Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings

Thursday, May 19, 2011 General News J E 4

Oral Abstract Data Presentation at ASCO, Chicago (June 3 – 7, 2011)

Abstract #6508

Title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study. J.C. Byrd et al.

Date/Time: Monday, June 6, 2011; Oral Abstract Session: 9:30 AM – 12:30 PM

Session Title: Leukemia, Myelodysplasia and Transplantation

Location: Arie Crown Theater

Oral Abstract Data Presentations at ICML, Lugano, Switzerland (June 15-18, 2011)

Abstract # 122

Title: The Btk Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study.  S. O'Brien et al.

Date/Time: Friday, June 17, 2011; 9:45 AM

Session 10: Chronic Lymphocytic Leukemia (CLL)

Location: Room A, B, C and Marquee Parco Ciani)

Abstract # 153

Title: The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B-cell malignancies: Final results from a Phase Ia study.  R.H. Advani et al.

Date/Time: Saturday, June 18, 2011; 9:30 AM

Session 14:  Signaling Pathways in Lymphoma

Location: Room A



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Nektar Announces New Phase 2 Data for NKTR-102 to ...
Silence Therapeutics to Present New Data from Phas...